BusinessGalectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development ProgramsBy Nasdaq OMXJan 25, 2018, 1:31 PM UTC
BusinessGalectin Therapeutics to Webcast Corporate Update at Annual Meeting of ShareholdersBy Nasdaq OMXDec 11, 2017, 2:00 PM UTC
BusinessGalectin Therapeutics Announces Results from Phase 2b NASH-CX TrialBy Nasdaq OMXDec 5, 2017, 1:15 PM UTC
BusinessGalectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business UpdateBy Nasdaq OMXNov 7, 2017, 1:15 PM UTC
BusinessGalectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH CirrhosisBy Nasdaq OMXOct 20, 2017, 12:30 PM UTC
BusinessOcera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting®By Nasdaq OMXOct 20, 2017, 11:30 AM UTC
BusinessOcera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting® 2017By Nasdaq OMXAug 23, 2017, 1:05 PM UTC
BusinessGalectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business UpdateBy Nasdaq OMXAug 14, 2017, 12:15 PM UTC
